ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1177

Pregnancy Outcomes in Women with Familial Mediterranean Fever Treated with Anakinra: A Retrospective Study

Bilgesu Ergezen1, Ozgur Can Kilinc2, Bugra Egeli3, Oguzhan Omer Kizilkaya2, Kerem parlar4, Enes Azman2, Huri ozdogan1 and serdal Ugurlu5, 1Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, İstanbul, Turkey, 2Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey, 3Children's Hospital of Los Angeles, Los Angeles, CA, 4Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, İstanbul, Turkey, 5Istanbul University-Cerrahpasa, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Meeting: ACR Convergence 2025

Keywords: Biologicals, FMF, pregnancy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Familial Mediterranean Fever (FMF) is an autoinflammatory disease mainly treated with colchicine. Anakinra, an interleukin-1 receptor antagonist, is used for colchicine-resistant cases. However, data on the safety of Anakinra during pregnancy is limited. This study aims to evaluate pregnancy outcomes of FMF patients who received at least one dose of Anakinra during pregnancy.

Methods: A retrospective single-center study was conducted to analyze clinical data and pregnancy outcomes of FMF patients who received Anakinra during pregnancy.

Results: This study included data from 27 pregnancies involving 19 mothers. The average maternal age at pregnancy was 31.5 ± 3.95 years. The most common genotype among mothers was homozygous M694V, observed in %72.2 (13/18) of cases. Amyloidosis was present in %15.8 (3/19) of mothers. In %51.9 (14/27) of the pregnancies, mothers were on Anakinra treatment prior to pregnancy, while in the remaining pregnancies Anakinra treatment was started during pregnancy. Out of the 27 pregnancies, 26 resulted in delivery, and one is still ongoing at 15 weeks of gestation. Among the terminated pregnancies, 26 babies were born, one of whom was stillborn. The frequency of cesarean section was 80.8% (21/26), and the rate of preterm birth was 34.6% (9/26), with an average gestational age at birth of 36.6 ± 3.3 weeks. Assisted reproduction techniques were utilized in %30.4 (7/23) of the pregnancies. The most common maternal complication during pregnancy was preeclampsia (5/23) followed by bleeding (2/23), hypertension (2/23), gestational diabetes (1/23), and cerebrovascular event (1/23). Intrauterine growth restriction was reported in %18.5 (5/27) of the pregnancies. The rate of neonatal ICU hospitalization was %16.7 (4/24) among babies. It was reported that %34.8 (8/23) of the babies were small for gestational age. Mean weight, length, and head circumference of the babies were 2.8 ± 0.76 kg, 46.5 ± 6.2 cm, and 33.8 ± 3.8 cm, respectively. The average Apgar scores at first and fifth minutes were 7.8 ± 1.4 and 9.0 ± 1.1, respectively. The average current age of the children is 75.3 ± 45.9 months, with a mean weight of 26.7 ± 11.4 kg and mean height of 116.4 ± 22.8 cm. Among these children, the most common chronic condition was allergic conditions (4/9), followed by growth hormone deficiency (1/9), PFAPA (1/9), torticollis (1/9), and a heart murmur (1/9).

Conclusion: Although complications such as preeclampsia and intrauterine growth restriction were observed, no lasting sequelae were reported in the children, and the majority of pregnancies resulted in live births with favorable outcomes. Anakinra appears to be safe during pregnancy, with no major teratogenic effects identified. However, long-term follow-up is warranted to fully assess potential outcomes.

Supporting image 1Maternal and Neonatal Characteristics of the Patient Population


Disclosures: B. Ergezen: None; O. Kilinc: None; B. Egeli: None; O. Kizilkaya: None; K. parlar: None; E. Azman: None; H. ozdogan: None; s. Ugurlu: None.

To cite this abstract in AMA style:

Ergezen B, Kilinc O, Egeli B, Kizilkaya O, parlar K, Azman E, ozdogan H, Ugurlu s. Pregnancy Outcomes in Women with Familial Mediterranean Fever Treated with Anakinra: A Retrospective Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/pregnancy-outcomes-in-women-with-familial-mediterranean-fever-treated-with-anakinra-a-retrospective-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pregnancy-outcomes-in-women-with-familial-mediterranean-fever-treated-with-anakinra-a-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology